Results 181 to 190 of about 150,656 (304)

A Parallel Group, 1:1 Randomised, Pilot Study Comparing the Clinical Efficacy and Bleeding Risk Between Low Dose and Standard Dose Intrapleural Tissue Plasminogen Activator for Adults With Pleural Infection. [PDF]

Respirol Case Rep
Chan KKP, Chan C, Hui DSC, Tan AL, Lee YCG.   +4 more
europepmc   +1 more source

Inhibition of PLA2G15 Alleviates Palmitic Acid‐Induced Lysosomal Membrane Permeabilization in Human Nucleus Pulposus Cells During Intervertebral Disc Degeneration

JOR SPINE, Volume 9, Issue 2, June 2026.
LMP is responsible for lysosomal dysfunction in IDD. The lipid composition changes in the lysosomal membrane, mediated by PLA2G15, are the cause of LMP. The C/EBPα significantly promotes PLA2G15 expression under PA overload stress. Inhibition of PLA2G15 alleviates PA‐induced LMP by inhibiting the hydrolysis of lysosomal membrane phospholipids. ABSTRACT
Liqun Duan, Jiang Jiang, Shuangshuang Tu, Chuanfu Li, Yijun Dong, Yongjin Li, Wenzhi Zhang, Xi Chen   +7 more
wiley   +1 more source

Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors. [PDF]

Am Heart J Plus
Jalili J, Vaseghi S, Asvadi T, Baastani Khajeh M.   +3 more
europepmc   +1 more source

Management of neonatal massive hemorrhage: A narrative review

Transfusion, EarlyView.
Cheryl S. L. Chooi, Mary Claire Simmonds, Laura Fisher, Tara Crawford, Michael J. Stark, Scott Morris, Marcus Brecht, Fiona Taverner   +7 more
wiley   +1 more source

Transcriptomic analysis reveals the hepatic response mechanisms of the Chinese spiny frog (Quasipaa spinosa) to Citrobacter freundii infection

Journal of the World Aquaculture Society, Volume 57, Issue 3, June 2026.
Abstract To elucidate the pathogen and host response mechanisms underlying mass mortality in Quasipaa spinosa, dominant bacteria were isolated from diseased individuals and identified as Citrobacter freundii by morphological, physiological, and biochemical characterization, 16S rRNA sequencing, and phylogenetic analysis.
Yanhong Li, Baohong Zhou, Yiran Lu, Yi Zang, Minghao Hu, Qiaochen Jin, Wenbin Fang, Shanjian Zheng   +7 more
wiley   +1 more source

Subretinal injection of tissue plasminogen activator for submacular hemorrhage - When and how to do.

Oman J Ophthalmol
Sriram R, Manayath GJ.
europepmc   +1 more source

A Multicenter, Open-Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial. [PDF]

Pharmacotherapy
Stringer KA, Goldberg D, Chen S, Thrush P, Graham EM, Lubert A, Myers J, McLellan L, Flott T, Nasr S, Schumacher KR.   +10 more
europepmc   +1 more source

DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long‐Term Survival in Ischemic Stroke: A Prospective Cohort Study

Annals of Neurology, Volume 99, Issue 5, Page 1210-1223, May 2026.
Objective Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation.
B. Díaz‐Benito, P. Calleja, L. Alzamora, A. Ruiz‐García, A. Martínez‐Salio, M. Muñoz‐García, F. Ostos, A. García‐Culebras, A. Moraga, M.A. Moro, I. Lizasoain   +10 more
wiley   +1 more source

Tissue Plasminogen Activator to Resolve Elevated Purge System Pressure in a Catheter-Based Ventricular Assist Device. [PDF]

JACC Case Rep
Khattak S, Shamkhani W, Maqableh GM, Al-Shatanawi A, Khan SQ.   +4 more
europepmc   +1 more source

Individualized Treatment in Distal and Medium Vessel Occlusion Stroke Using a Validated Explainable Counterfactual Treatment Estimation Model

Annals of Neurology, Volume 99, Issue 5, Page 1198-1209, May 2026.
Objective The optimal treatment for distal medium vessel occlusion (DMVO) stroke remains uncertain, and evidence comparing endovascular therapy (EVT) with medical management (MM) is limited. We aimed to develop and validate a predictive modeling tool to assess individual treatment benefit in DMVO stroke using explainable counterfactual treatment ...
Mohamed F. Doheim, Mahmoud H. Mohammaden, Hend Abdelhamid, Marta Olive‐Gadea, Marc Rodrigo‐Gisbert, Manuel Requena, Johanna T. Fifi, James E. Siegler, Santiago Ortega‐Gutierrez, Mohamad Abdalkader, Ali Alaraj, Wei Hu, Thanh N. Nguyen, Diogo C. Haussen, Raul G. Nogueira   +14 more
wiley   +1 more source